Effectiveness and safety of Tadalafil-SZ (NJSC “Northern Star”) at 5 mg / day in patients with symptoms of voiding dysfunction due to prostatic hyperplasia

Abstract

The study objective is to evaluate effectiveness and safety of Tadalafil-SZ (NJSC “Northern Star”) at 5 mg / day in treatment of patients with symptoms of voiding dysfunction due to prostatic hyperplasia.Materials and methods. The study was conducted at the “Family Polyclinic No. 4” between January and June of 2019 and included 74 patients. Effectiveness was evaluated using the International Prostatic Symptom Score, International Index of Erectile Function, maximum urine flow rate and transrectal ultrasound examination.Results. After 3 months of therapy with tadalafil, positive dynamics of all characteristics were observed. Symptom severity prior to treatment was 11.50 ± 0.27 points, after treatment it was 10.00 ± 0.31 points. Maximum urine flow rate prior to treatment was 10.80 ± 0.20 ml / s, after treatment it was 11.10 ± 0.19 ml / s. The International Index of Erectile Function increased from 16.60 ± 0.30 prior to treatment to 20.20 ± 0.24 after treatment. Prostate volume before treatment was 43.70 ± 0.87 cm3, after treatment it was 40.30 ± 0.72 cm3.Conclusion. Tadalafil at 5 mg / day significantly decreases symptoms of voiding dysfunction and prostate volume, improves erectile function.

Keywords

• voiding dysfunction
• prostatic hyperplasia
• erectile function
• tadalafil